Plasminogen activation and thrombolysis for ischemic stroke

International Journal of Stroke

Volumn 7, Issue 5, 2012, Pages 419-425

  Medcalf, Robert L ^a   Davis, Stephen M ^b,c  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acute stroke therapy; Ischemic stroke; MRI; RtPA; Thrombolysis

Indexed keywords

DESMOTEPLASE; FIBRINOLYTIC AGENT; PLACEBO; PROUROKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; REVIEW; TELEMEDICINE;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; META-ANALYSIS AS TOPIC; MICE; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84862691077     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2012.00783.x     Document Type: Review

References (79)

1. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129:307-321.
2. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost 2007; 5(Suppl. 1):132-142.
3. Longstaff C, Williams S, Thelwell C. Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem 2008; 6:212-223.
4. Haeberle JR, Sutton TA, Trockman BA. Phosphorylation of two sites on smooth muscle myosin. Effects on contraction of glycerinated vascular smooth muscle. J Biol Chem 1988; 263:4424-4429.
5. NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-1587.
6. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004; 61:1066-1070.
7. Saver JL. Time is brain-quantified. Stroke 2006; 37:263-266.
8. Ahmed N, Wahlgren N, Grond M etal. Implementation and outcome of thrombolysis with alteplase 3-4·5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010; 9:866-874.
9. Hacke W, Donnan G, Fieschi C etal. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363:768-774.
10. Hacke W, Kaste M, Fieschi C etal. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
11. Hacke W, Kaste M, Fieschi C etal. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352:1245-1251.
12. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282:2019-2026.
13. Darby DG, Barber PA, Gerraty RP etal. Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI. Stroke 1999; 30:2043-2052.
14. Wahlgren N, Ahmed N, Eriksson N etal. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke 2008; 39:3316-3322.
15. Hoffman JR, Cooper RJ. Stroke thrombolysis: we need new data, not more reviews. Lancet Neurol 2005; 4:204-205.
16. Ingall TJ, O'fallon WM, Asplund K etal. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004; 35:2418-2424.
17. Hacke W, Kaste M, Bluhmki E etal. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.
18. Wahlgren N, Ahmed N, Davalos A etal. Thrombolysis with alteplase 3-4·5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372:1303-1309.
19. Lees KR, Bluhmki E, Von Kummer R etal. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375:1695-1703.
20. Davis S, Donnan G. The ECASS III results and the t-PA paradox. Int J Stroke 2009; 4:17-18.
21. Audebert HJ, Schenkel J, Heuschmann PU, Bogdahn U, Haberl RL. Effects of the implementation of a telemedical stroke network: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria, Germany. Lancet Neurol 2006; 5:742-748.
22. Davis SM, Hand PJ, Donnan GA. Tissue plasminogen activator for ischaemic stroke: highly effective, reasonably safe and grossly underused. Med J Aust 2007; 187:548-549.
23. Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010; 41:2840-2848.
24. Mishra NK, Ahmed N, Andersen G etal. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010; 341:c6046.
25. Ford GA, Ahmed N, Azevedo E etal. Intravenous alteplase for stroke in those older than 80 years old. Stroke 2010; 41:2568-2574.
26. Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005; 36:2497-2499.
27. Mishra NK, Davis SM, Kaste M, Lees KR. Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care 2010; 33:2531-2537.
28. Whiteley W, Lindley R, Wardlaw J, Sandercock P. Third International Stroke Trial. Int J Stroke 2006; 1:172-176.
29. Zhou XY, Wang SS, Collins ML, Davis SM, Yan B. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J Clin Neurosci 2010; 17:988-992.
30. Albers GW, Thijs VN, Wechsler L etal. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006; 60:508-517.
31. Davis SM, Donnan GA, Parsons MW etal. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008; 7:299-309.
32. Hacke W, Albers G, Al-Rawi Y etal. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:66-73.
33. Furlan AJ, Eyding D, Albers GW etal. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37:1227-1231.
34. Hacke W, Furlan AJ, Al-Rawi Y etal. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8:141-150.
35. Straka M, Albers GW, Bammer R. Real-time diffusion-perfusion mismatch analysis in acute stroke. J Magn Reson Imaging 2010; 32:1024-1037.
36. Campbell BC, Christensen S, Levi CR etal. Cerebral blood flow is the optimal CT perfusion parameter for assessing infarct core. Stroke 2011; 42:3435-3440.
37. Samson AL, Medcalf RL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron 2006; 50:673-678.
38. Yepes M, Lawrence DA. New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp Biol Med 2004; 229:1097-1104.
39. Sappino AP, Madani R, Huarte J etal. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993; 92:679-685.
40. Carmeliet P, Schoonjans L, Kieckens L etal. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368:419-424.
41. Baranes D, Lederfein D, Huang YY, Chen M, Bailey CH, Kandel ER. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 1998; 21:813-825.
42. Pawlak R, Magarinos AM, Melchor J, Mcewen B, Strickland S. Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat Neurosci 2003; 6:168-174.
43. Pawlak R, Melchor JP, Matys T, Skrzypiec AE, Strickland S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc Natl Acad Sci U S A 2005; 102:443-448.
44. Zhou Y, Maiya R, Norris EH, Kreek MJ, Strickland S. Involvement of tissue plasminogen activator in stress responsivity during acute cocaine withdrawal in mice. Stress 2010; 13:481-490.
45. Maiya R, Zhou Y, Norris EH, Kreek MJ, Strickland S. Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc Natl Acad Sci U S A 2009; 106:1983-1988.
46. Nagai T, Kamei H, Ito M etal. Modification by the tissue plasminogen activator-plasmin system of morphine-induced dopamine release and hyperlocomotion, but not anti-nociceptive effect in mice. J Neurochem 2005; 93:1272-1279.
47. Bahi A, Kusnecov A, Dreyer JL. The role of tissue-type plasminogen activator system in amphetamine-induced conditional place preference extinction and reinstatement. Neuropsychopharmacology 2008; 33:2726-2734.
48. Madani R, Hulo S, Toni N etal. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 1999; 18:3007-3012.
49. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and t-PA. Nature 1996; 384:123-124.
50. Nicole O, Docagne F, Ali C etal. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7:59-64.
51. Mori T, Wang X, Kline AE etal. Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma. Neuroreport 2001; 12:4117-4120.
52. Nagai N, De Mol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 1999; 99:2440-2444.
53. Echeverry R, Wu J, Haile WB, Guzman J, Yepes M. Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus. J Clin Invest 2010; 120:2194-2205.
54. Correa F, Gauberti M, Parcq J etal. Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med 2011; 208:1229-1242.
55. Benchenane K, Berezowski V, Fernandez-Monreal M etal. Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke 2005; 36:1065-1070.
56. Su EJ, Fredriksson L, Geyer M etal. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14:731-737.
57. Su EJ, Fredriksson L, Schielke GP, Eriksson U, Lawrence DA. Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke. J Thromb Haemost 2009; 7(Suppl. 1):155-158.
58. Benchenane K, Berezowski V, Ali C etal. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 2005; 111:2241-2249.
59. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112:1533-1540.
60. Abu Fanne R, Nassar T, Yarovoi S etal. Blood-brain barrier permeability and t-PA-mediated neurotoxicity. Neuropharmacology 2010; 58:972-980.
61. Kidwell CS, Latour L, Saver JL etal. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis 2008; 25:338-343.
62. Kassner A, Roberts TP, Moran B, Silver FL, Mikulis DJ. Recombinant tissue plasminogen activator increases blood-brain barrier disruption in acute ischemic stroke: an MR imaging permeability study. AJNR Am J Neuroradiol 2009; 30:1864-1869.
63. Traynelis SF, Lipton SA. Is tissue plasminogen activator a threat to neurons? [letter; comment.]. Nat Med 2001; 7:17-18.
64. Benchenane K, Lopez-Atalaya JP, Fernandez-Monreal M, Touzani O, Vivien D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci 2004; 27:155-160.
65. Medcalf R. Plasminogen activation-based thrombolysis for ischaemic stroke: the diversity of targets may demand new approaches. Curr Drug Targets 2011; 12:1772-1781.
66. Donnan GA, Davis SM, Chambers BR etal. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276:961-966.
67. Longstaff C, Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Lett 2005; 579:3303-3309.
68. Keyt BA, Paoni NF, Refino CJ etal. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A 1994; 91:3670-3674.
69. Kratzschmar J, Haendler B, Langer G etal. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene 1991; 105:229-237.
70. Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012; 165:75-89.
71. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34:537-543.
72. Reddrop C, Moldrich RX, Beart PM etal. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005; 36:1241-1246.
73. Lopez-Atalaya JP, Roussel BD, Levrat D etal. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J Cereb Blood Flow Metab 2008; 28:1212-1221.
74. Parsons MW, Miteff F, Bateman GA etal. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology 2009; 72:915-921.
75. Amano M, Ito M, Kimura K etal. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 1996; 271:20246-20249.
76. Furlan A, Higashida R, Wechsler L etal. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999; 282:2003-2011.
77. Smith WS, Sung G, Saver J etal. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke 2008; 39:1205-1212.
78. Baker WL, Colby JA, Tongbram V etal. Neurothrombectomy devices for the treatment of acute ischemic stroke: state of the evidence. Ann Intern Med 2011; 154:243-252.
79. Khatri P, Hill MD, Palesch YY etal. Methodology of the interventional management of stroke III trial. Int J Stroke 2008; 3:130-137.